Table 5.

Treatment persistence rates and biochemical parameters among patients switched to weekly or bi-weekly SC CT-P13 in patients on escalated intravenous infliximab dosing frequency prior to switch.

	Every other week [n = 27]	Weekly [n = 23]	p-value
Treatment persistence rates
3 months	100%	96.3%	0.353
6 months	92.6%	95.7%	0.357
12 months	92.6%	95.7%	0.650
C-reactive protein [mg/L]
Baseline	3.0 [4.0]	1.0 [2.0]	0.014
3 months	2.0 [4.0]	1.0 [1.0]	0.019
6 months	2.5 [4.0]	2.0 [1.0]	0.112
12 months	3.5 [4.0]	1.0 [2.0]	0.015
Faecal calprotectin [µg/g]
Baseline	73.0 [1070.5]	38.0 [125.0]	0.782
3 months	201.0 [193.0]	36.0 [67.0]	0.752
6 months	79.0 [331.5]	49.0 [121.0]	0.476
12 months	183.0 [306.5]	30.0 [86.0]	0.373
Infliximab levels [µg/dl]
Baseline	11.9 [9.2]	12.4 [8.7]	0.338
3 months	16.0 [2.6]	16.0 [0.0]	0.431
6 months	16.0 [7.3]	16.0 [0.0]	0.909
12 months	16.0 [2.4]	16.0 [0.0]	0.823

SC, subcutaneous.